Lilly inks second deal with Asian partner this week

The Indianapolis pharma signed a second deal with an Asian company in as many days. Eli Lilly & Co announced on 20 March that it will pay $56m up front to Chinese biotech Innovent Biologics to collaborate on several oncology compounds.

The Indianapolis pharma signed a second deal with an Asian company in as many days. Eli Lilly & Co announced on 20 March that it will pay $56m up front to Chinese biotech Innovent Biologics to collaborate on several oncology compounds.

The deal comes just a day after Lilly inked a collaboration with Korea's Hanmi Pharmaceuticals for $690m to work on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category